CAR T-cell therapy is a treatment that re-engineers a patient’s T-cells with synthetic proteins called chimeric antigen receptors (CARs) which enhance the T-cell’s ability to recognise and kill cancer cells.
CAR T-cell therapy has proven effective in some diseases including B-cell malignancies, however, it is not effective in all patient populations.
CAR T-cell therapy continues to be a topic of ongoing clinical research nationally and internationally.
By the end of this rapid learning you will be able to:
Viewing this on mobile? Tell us what you thought. Complete the survey.
This Rapid Listening, we hear from Erica Smeaton, National Nurse Manager at Lymphoma Australia who shares their experience with CAR T-cell therapy.
Download the eviQ Education app to access exclusive content.
Use the QR code to access to CAR T-cell therapy mini quiz, or visit our mini quizzes homepage for more information.
CAR T-cell therapy referral centres and contacts